Little Green Pharma selected to supply France’s medical cannabis pilot program

Little Green Pharma selected to supply France’s medical cannabis pilot program
Share this article

 

MONTRÉAL – Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) reported the latest achievements of its largest holding Little Green Pharma Ltd. LGP has achieved the following major milestone validating their investment:

The French Agency for the Safety of Medicines and Health Products (ANSM) has selected Little Green Pharma as 1 of 4 companies that will supply France’s medical cannabis pilot program. Under the program, participants will be provided with free products to patients that enol in the trial. LGP will be both a main & substitute supplier for CBD sublingual oils.

Currently, Elixxer holds 27.4M shares of LGP and as of January 27, 2021 the closing price was $0.64 per share on the ASX.

Elixxer says it will update the investors via press release on further developments from its holdings.

Elixxer is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US OTC-QB exchange (OTCQB: ELIXF).

Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.

 

We seek Safe Harbor.

 

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.